Claims
- 1. A compound having the formula: ##STR5## where X is an amino-group containing substance whose amino nitrogen forms an amide link with the carbonyl group of the cyclohexene-1, 2,dicarboxylic acid function; R.sub.1, R.sub.2, and R.sub.3 are independently selected from hydrogen, alkyl, or phenyl groups; and F comprises an organic macromolecule function from which the amino-group containing substance is to be released.
- 2. The compound of claim 1 wherein X comprises a polypeptide residue.
- 3. The compound of claim 2 wherein the polypeptide is a drug or an enzyme.
- 4. The compound of claim 1 wherein X is a residue of a cytotoxin.
- 5. The compound of claim 4 wherein X is a residue of a cytotoxin that inactivates cellular protein synthesis.
- 6. The compound of claim 4 wherein X is a residue of pokeweed antiviral protein, ricin A-chain, abrin A-chain, modeccin A-chain or gelonin.
- 7. The compound of claim 1 wherein F comprises a polymeric carrier, an antibody, or a binding partner for a cell-surface receptor.
- 8. The compound of claim 1 wherein F is ##STR6## and A comprises the organic macromolecule.
- 9. The compound of claim 8 wherein A is selected from:
- (a) polymeric carriers;
- (b) N-alkyl maleimido-linked polypeptides; and
- (c) thioether-linked polypeptides.
- 10. The compound of claim 1 wherein R.sub.1, R.sub.2, and R.sub.3 are each --H.
- 11. The compound of claim 7 wherein F comprises an antibody that is specific for a cell surface receptor of said cell type.
- 12. The compound of claim 7 wherein F comprises an antibody to a T-cell surface antigen.
- 13. The compound of claim 12 wherein said T-cell surface antigen is T3, T4, T11, or T12.
- 14. The compound of claim 7 wherein F comprises an antibody to a tumor associated surface antigen.
- 15. The compound of claim 7 wherein F comprises J5 antibody.
- 16. The compound of claim 7 wherein F comprises a binding partner for said cell receptor of cells of a desired cell type, said compound selectively binding to cells of said cell type, being internalized by said cells by cytosis, and being cleaved in acidified organelles of said cells.
- 17. The compound ##STR7## where: (a) R.sub.1, R.sub.2, R.sub.3 are independently selected from hydrogen, alkyl, or phenyl groups;
- (b) T is selected from --OH, ##STR8## where Z is an N-alkyl maleimido group, I--CH.sub.2 -- or Br--CH.sub.2 --; and
- (c) U and V are independently selected from --OH, and OR.sub.4 (R.sub.4 being a benzyl group or an alkyl group of C.sub.5 or less).
- 18. The compound of claim 17 wherein R.sub.1, R.sub.2, and R.sub.3 are each --H.
- 19. A method of using the compound of claim 16 comprising
- providing said compound, and
- administering said compound to a heterogeneous cell population comprising said cell type and other cells,
- said compound selectively binding to and being internalized by said cell type, and being cleaved in an organelle of said cell type responsible for protein synthesis.
- 20. A method of making the compound of claim 8 comprising the steps:
- (a) providing one of the following reagents, ##STR9## where: X is defined in claim 1, r=1-5, R.sub.1, R.sub.2, R.sub.3 are defined as in claim 8, R.sub.5 is --CH.sub.2 I or --CH.sub.2 Br;
- (b) reacting said reagent with a functionalized antibody.
Parent Case Info
This application is a continuation-in-part of co-pending, commonly owned U.S. patent application Ser. No. 733,479 now U.S. Pat. No. 4,618,492, filed on May 13, 1985 and which is a Divisional application of commonly owned U.S. patent application Ser. No. 645,614, now U.S. Pat. No. 4,542,225, filed Aug. 29, 1984 by Walter A. Blattler, John M. Lambert, and Peter D. Senter, which applications are hereby incorporated by reference.
Government Interests
This invention was made with Government support. The Government has certain rights in this invention.
US Referenced Citations (7)
Non-Patent Literature Citations (12)
Entry |
Carlsson et al., Biochem. J. (1978), vol. 173, pp. 723-737, "Protein Thiolation and Reversible Protein-Protein Conjugation". |
Cleland, W. W. (1964), Bioch. 3:480. |
Lutter et al., (1974), FEBS Letters, 48:288-292. |
Shen and Ryser (1981), Biochem. and Biophys. Res. Commun., 102(3):1048-1054. |
Vitetta et al. (1983), Science 219:644-650. |
Edwards (1983), Pharmacol. Ther. 23:147-177. |
Ramakrizhnan et al. (1984), Cancer Research 44:1398-1404. |
Ritz et al. (1980), Nature, 283:583-585. |
Barbieri et al. (1982), Biochem. J., 203:55-59. |
Stirpe et al. (1980), J. Biol. Chem., 255:6947-6953. |
Kirby et al. (1970), Proc. Biochem. Soc. Symp., 31:99-103. |
Dixon et al. (1968), Biochem. J., 109:312-314. |
Divisions (1)
|
Number |
Date |
Country |
Parent |
645614 |
Aug 1984 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
733479 |
May 1985 |
|